How shall we treat locally advanced triple negative breast cancer? [version 2; peer review: 2 approved]
Triple negative breast cancer (TNBC) has been shown to respond to neoadjuvant chemotherapy (NACT). It has been established that achieving pathological complete response (pCR) for certain aggressive subtypes of breast cancer, including HER-2 (over-expressed) and TNBC, provides an important surrogate...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2020-05-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/8-1649/v2 |
| _version_ | 1818511263744917504 |
|---|---|
| author | Paulo Luz David Dias Ana Fortuna Luis Bretes Beatriz Gosalbez |
| author_facet | Paulo Luz David Dias Ana Fortuna Luis Bretes Beatriz Gosalbez |
| author_sort | Paulo Luz |
| collection | DOAJ |
| description | Triple negative breast cancer (TNBC) has been shown to respond to neoadjuvant chemotherapy (NACT). It has been established that achieving pathological complete response (pCR) for certain aggressive subtypes of breast cancer, including HER-2 (over-expressed) and TNBC, provides an important surrogate marker for predicting long-term clinical response and survival outcomes. How to increase the number of patients that achieve pCR remains challenging. Platinum-based NACT seems to be part of the solution and capecitabine, an active drug in metastatic breast cancer, but not a standard one in earlier stages may have found its place in the adjuvant setting. In the near future immunotherapy can play a role in early TNBC |
| first_indexed | 2024-12-10T23:30:59Z |
| format | Article |
| id | doaj.art-95a95514cbdd4b71b050876e6bf89cdf |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-10T23:30:59Z |
| publishDate | 2020-05-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-95a95514cbdd4b71b050876e6bf89cdf2022-12-22T01:29:23ZengF1000 Research LtdF1000Research2046-14022020-05-01810.12688/f1000research.20509.226216How shall we treat locally advanced triple negative breast cancer? [version 2; peer review: 2 approved]Paulo Luz0David Dias1Ana Fortuna2Luis Bretes3Beatriz Gosalbez4Medical Oncology, Centro Hospitalar Universitário do Algarve, Faro, PortugalMedical Oncology, Centro Hospitalar Universitário do Algarve, Faro, PortugalMedical Oncology, Centro Hospitalar Universitário do Algarve, Faro, PortugalMedical Oncology, Centro Hospitalar Universitário do Algarve, Faro, PortugalMedical Oncology, Centro Hospitalar Universitário do Algarve, Faro, PortugalTriple negative breast cancer (TNBC) has been shown to respond to neoadjuvant chemotherapy (NACT). It has been established that achieving pathological complete response (pCR) for certain aggressive subtypes of breast cancer, including HER-2 (over-expressed) and TNBC, provides an important surrogate marker for predicting long-term clinical response and survival outcomes. How to increase the number of patients that achieve pCR remains challenging. Platinum-based NACT seems to be part of the solution and capecitabine, an active drug in metastatic breast cancer, but not a standard one in earlier stages may have found its place in the adjuvant setting. In the near future immunotherapy can play a role in early TNBChttps://f1000research.com/articles/8-1649/v2 |
| spellingShingle | Paulo Luz David Dias Ana Fortuna Luis Bretes Beatriz Gosalbez How shall we treat locally advanced triple negative breast cancer? [version 2; peer review: 2 approved] F1000Research |
| title | How shall we treat locally advanced triple negative breast cancer? [version 2; peer review: 2 approved] |
| title_full | How shall we treat locally advanced triple negative breast cancer? [version 2; peer review: 2 approved] |
| title_fullStr | How shall we treat locally advanced triple negative breast cancer? [version 2; peer review: 2 approved] |
| title_full_unstemmed | How shall we treat locally advanced triple negative breast cancer? [version 2; peer review: 2 approved] |
| title_short | How shall we treat locally advanced triple negative breast cancer? [version 2; peer review: 2 approved] |
| title_sort | how shall we treat locally advanced triple negative breast cancer version 2 peer review 2 approved |
| url | https://f1000research.com/articles/8-1649/v2 |
| work_keys_str_mv | AT pauloluz howshallwetreatlocallyadvancedtriplenegativebreastcancerversion2peerreview2approved AT daviddias howshallwetreatlocallyadvancedtriplenegativebreastcancerversion2peerreview2approved AT anafortuna howshallwetreatlocallyadvancedtriplenegativebreastcancerversion2peerreview2approved AT luisbretes howshallwetreatlocallyadvancedtriplenegativebreastcancerversion2peerreview2approved AT beatrizgosalbez howshallwetreatlocallyadvancedtriplenegativebreastcancerversion2peerreview2approved |